We recently published a list of These 10 Stocks Already Sank in June. In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other worst performers on Monday.
Corcept Therapeutics dropped for a third consecutive day on Monday, shedding 7.58 percent to end at $71.68 apiece as investors appeared to have taken early profits from its intra-day surge.
At intra-day trading, Corcept Therapeutics Incorporated rallied to as high as $86.02 following news that its pivotal Phase 3 ROSELLA trial for the treatment of ovarian cancer achieved its primary endpoint of improved progression-free survival.
A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders.
Investors booked early profits to pull the company’s share price down toward the end of the session.
Corcept Therapeutics Incorporated said that patients who received relacorilant combined with nab-paclitaxel chemotherapy, experienced a 30 percent reduction in risk of disease progression, compared with patients who received nab-paclitaxel monotherapy.
An interim analysis of overall survival (OS), showed that the addition of relacorilant reduced the risk of death by 31 percent, substantially lengthening patients’ lives.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
This article is originally published at Insider Monkey.
